DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT03642600

CompletedPhase 4

The Gut Microbiome in Women With Polycystic Ovary Syndrome

Novel Strategies in Weight Loss in Women With Polycystic Ovary Syndrome: do Changes in the Gut Microbiome Play a Role?

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

21

actual

Study population

Obesity / overweight, PCOS

Key I/E criteria

•BMI ≥27•Female

Primary endpoint

•Weight loss

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03642600
Org study IDS61338

Timeline

Milestones

Study first posted2018-08-22actual
Study start2019-02-28actual
Primary completion2020-02-01actual
Study completion2020-07-03actual
Last update posted2020-11-04actual

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweightPCOS

Eligibility

Who can enroll

Minimum age18 Years
Maximum age40 Years
SexFemale
Healthy volunteersNot accepted

Inclusion criteria

•PCOS according to ROtterdam criteria
•BMI ≥ 27 kg/m2 and at risk of metabolic syndrome or BMI ≥ 30 kg/m2

Exclusion criteria

•pregnancy
•pancreatitis (in the past)
•oral contraceptive pill use
•inflammatory bowel disease
•auto-immune disease
•immuno-modulatory drugs
•antidiabetic drugs
•anti-inflammatory drugs

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

1 endpoint
Primary/protocol endpoint/low confidence

weight loss

Time frame:32 weeks

descriptive, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.